scout
|Videos|August 10, 2017

Dr. Schmoll on the Objective of CHARTA for CRC

Hans-Joachim Schmoll, MD, head, Department of Oncology and Hematology, associate professor, Internal Medicine, Hematology/ Oncology, University Hospital Halle, discusses the objective of the CHARTA study for patients with colorectal cancer (CRC).

Hans-Joachim Schmoll, MD, head, Department of Oncology and Hematology, associate professor, Internal Medicine, Hematology/ Oncology, University Hospital Halle, discusses the objective of the CHARTA study for patients with colorectal cancer (CRC).

The CHARTA trial investigates the potential activity of FOLFOX plus bevacizumab (Avastin) with or without irinotecan, explains Schmoll. The primary endpoint of the study was the improvement of progression-free survival at 9 months.

Newsletter

Stay up to date on the most recent and practice-changing oncology data


Latest CME